The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) posted a 14.4% year-on-year (YoY) increase in consolidated profits attributable to the parent company during the first nine months of 2025, according to the financial statements filed to the Egyptian Exchange (EGX) on November 11th.

Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) will disburse EGP 0.10642 per share in cash dividends to shareholders.

The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) posted a 44.26% year-on-year (YoY) leap in consolidated net profits attributable to the parent company in the first quarter (Q1) of 2025, achieving EGP 82.243 million from EGP 57.009 million.

The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents’ (Rameda) ordinary general meeting (OGM) approved the distribution of cash dividends valued at EGP 160 million for 2024 to shareholders over two equal installments.

The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) posted a 58.2% year-on-year (YoY) uptick in consolidated profits attributable to the parent company in 2024 to EGP 387.366 million versus EGP 244.859 million.

The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) posted a 22.17% year-on-year (YoY) increase in consolidated profits attributable to the parent company during the first nine months of 2024.

Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) has completed its largest acquisition to date, securing a top-selling anti-diabetic product used to treat type 2 diabetes.

The Financial Regulatory Authority (FRA) has approved publishing the disclosure form proposed by the Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents’ (Rameda) board to decrease its issued and paid up capital via writing off 9.47 million treasury shares.

The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) has established a new subsidiary, Glow, that will specialize in producing freely priced cosmetics and cosmeceuticals.

The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) is planning to increase its export revenue share to 20% within the next five years, up from the current 12%.

The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) reported a 2.74% year-on-year decline in consolidated net profit excluding minority interest for the first half (H1) of 2024, according to the consolidated financial statement filed to the Egyptian Exchange (EGX) on August 13th.

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) has received approval from the Egyptian Drug Authority (EDA) for price increases on all its major products.

The Egyptian Exchange’s (EGX) listing committee has approved listing an increase of EGP 3.234 million for Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) issued and paid-up capital.

Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) will disburse EGP 0.0670 per share in cash dividends to shareholders, as per a disclosure.

The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) posted a 14.3% year-on-year (YoY) decline in consolidated net profits attributable to the parent company in the first quarter (Q1) of 2024, achieving EGP 57.009 million from EGP 66.514 million.

The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) (RMDA) posted a 0.3% year-on-year (YoY) downtick in consolidated profits attributable to the parent company in 2023 to EGP 244.859 million, versus EGP 245.676 million.

Ramada is an Egypt-based pharmaceutical company that manufactures both human and veterinary pharmaceuticals. It operates three fully independent factories at its plant, including 20 production lines capable of producing a wide range of general medicinal forms, namely eye drops, solid dosage forms, syrups, blow-fill-seal, and lyophilized vials, among others.

The Egyptian Exchange’s (EGX) listing committee has approved listing the issued and paid-up capital increase of the Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda).

The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) (RMDA) will distribute 0.52253-for-1 bonus shares to shareholders as of September 21st.

Rameda is an Egypt-based pharmaceutical company that manufactures both human and veterinary pharmaceuticals.